Table 2.

Associations of RAAS Inhibitor Use With COVID‐19 Outcomes

Outcome	Rate of Outcome With RAAS Inhibitor Use vs Use of a CCB or TZD
	Intention‐to‐Treat			As‐Treated
	RAAS Inhibitor, n=115 684, No. of Events	CCB or TZD, n=48 927, No. of Events	HR (95% CI)	RAAS Inhibitor, n=115 684, No. of Events	CCB or TZD, n=48 927, No. of Events	HR (95% CI)
Hospitalization with COVID‐19	228	107	0.92 (0.70–1.22)	210	100	0.93 (0.67–1.29)
Death with COVID‐19	35	29	1.22 (0.68–2.19)	34	28	1.44 (0.64–3.27)
Hospitalization or death with COVID‐19 combined	246	121	0.97 (0.74–1.27)	228	114	0.98 (0.72–1.34)

Swedish residents on antihypertensive monotherapy with a RAAS inhibitor were compared with those on monotherapy with either a CCB or a TZD, in both intention‐to‐treat and as‐treated models. CCB indicates calcium channel blocker; HR, inverse probability of treatment‐weighted and multivariate‐adjusted Cox proportional hazard ratio; RAAS, renin‐angiotensin aldosterone system; and TZD, thiazide diuretic.